206 results on '"Málek, Filip"'
Search Results
2. Heart rate as an independent predictor of long term mortality of acute heart failure patients in sinus rhythm according to their ejection fraction: data from the AHEAD registry
3. (Commentary to the article The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies)
4. Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)
5. Long-term effect of fixed-dose combination of perindopril and bisoprolol in a patient with ischemic heart disease after an episode of heart failure with reduced left ventricular ejection fraction: an example from practice
6. Aktualizace 2023 Doporučených postupů pro diagnostiku a léčbu srdečního selhání Evropské kardiologické společnosti z roku 2021.
7. Výsledky dotazníkového šetření „Diagnostika a léčba pacientů se srdečním selháním v klinické praxi“.
8. Srdeční selhání
9. Novel Neuromodulation Approach to Improve Left Ventricular Contractility in Heart Failure: A First-in-Human Proof-of-Concept Study
10. Effect of sodium-glucose co-transporter-2 inhibitor empagliflozin on disease progression in a patient with heart failure and preserved ejection fraction
11. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial
12. AHEAD score — Long-term risk classification in acute heart failure
13. Dlouhodobý efekt fixní kombinace perindopril/ bisoprolol u pacienta s ischemickou chorobou srdeční po epizodě srdečního selhání se sníženou ejekční frakcí levé komory – příklad z praxe.
14. Role of eplerenone in the threatment of cardiovascular diseases
15. Comparison of hospitalized and ambulatory patients with heart failure in the Czech Republic and Europe. Data from the ESC Heart Failure Long-Term Registry
16. Komplexní přístup v léčbě srdečního selhání.
17. Komentář: Farmakoterapie ovlivňující průběh srdečního selhání se sníženou ejekční frakcí a její přínos.
18. Editorial ke článku "The year in cardiovascular medicine 2021: heart failure and cardiomyopathies"
19. (Multicentric Observational prospective cohort STudy of the Heart Failure outpatients management in the Czech Republic - MOST-HF. Rationale and Design)
20. Traditional and new biomarkers of congestion in heart failure
21. Effect of SGLT2 inhibitor empagliflozin on the stabilization of heart failure progress with the possibility of further interventions in a patient with HFrEF - a case report
22. Comparison of Patients with Reduced and Mildly Reduced Left Ventricular Ejection Fraction: Intermediate Data from the FAR NHL Registry
23. Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up—Data from FAR NHL Registry
24. Reaching betablockers target dose in elderly patients with chronic heart failure
25. (Commentary to the article "Optimizing Foundational Therapies in Patients With HFrEF. How Do We Translate These Findings Into Clinical Care?"
26. (Optimizing Foundational Therapies in Patients With HFrEF. How Do We Translate These Findings Into Clinical Care? Translation of the document prepared by the Czech Society of Cardiology)
27. (2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC.
28. New biomarkers and heart failure
29. Risk of in-hospital mortality identified according to the typology of patients with acute heart failure: Classification tree analysis on data from the Acute Heart Failure Database–Main registry
30. Arterial hypertension and chronic heart failure
31. Long-term survival following acute heart failure: The Acute Heart Failure Database Main registry (AHEAD Main)
32. Spinal cord stimulation in heart failure: effect on disease‐associated biomarkers
33. Long-term follow-up of a patient undergoing interatrial shunt device implantation for treatment of heart failure with a preserved ejection fraction
34. (Summary of 2021 ESC Guidelines for the diagnosis and treatment of heart failure)
35. Does previous hypertension affect outcome in acute heart failure?
36. ECG in patients with acute heart failure can predict in-hospital and long-term mortality
37. Efekt inhibitoru sodíko‑glukózového ko‑transporteru 2 empagliflozinu na vývoj onemocnění u pacienta se srdečním selháním a zachovalou ejekční frakcí.
38. Expert consensus on the importance of iron deficiency and the possibility of its correction in patients with heart failure
39. TCT-432 Greater Splanchnic Nerve Ablation in Chronic Heart Failure: Preserved Versus Reduced Left Ventricular Ejection Fraction
40. A fixed-dose combination as an opportunity to reduce the morbidity and mortality in patients with coronary artery disease
41. (Practical aspects of establishing of heart failure clinics)
42. (Expert consensus on the practical aspects of collaboration between cardiologists and diabetologists in the management of patients with chronic heart failure with reduced ejection fraction)
43. (Expert consensus statement on the significance of iron deficiency and the possibilities of its correction in patients with heart failure)
44. Correlation of lipoprotein(a) with the extent of coronary artery disease in patients with established coronary atherosclerosis: gender differences
45. Acute effect of spinal cord stimulation on autonomic nervous system function in patients with heart failure
46. Trends in the treatment and survival of heart failure patients: a nationwide population‐based study in the Czech Republic
47. Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first‐in‐human clinical trial
48. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure—results of the Acute HEart FAilure Database registry
49. 2021 ACC update of the heart failure guidelines
50. Účinek inhibitoru SGLT2 empagliflozinu na stabilizaci průběhu srdečního selhání s možností dalších intervencí u pacienta s HFrEF.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.